Introduction

Boc-L-His(Trt)-Aib-OH (CAS 2061897-68-3) is a protected amino acid derivative essential for synthesizing structurally complex and functionally stable peptides. Combining the acid-labile tert-butoxycarbonyl (Boc) protecting group, the trityl (Trt)-shielded histidine side chain, and the conformationally rigid α-aminoisobutyric acid (Aib), this compound addresses key challenges in peptide chemistry. Its CAS number, 2061897-68-3, ensures precise identification in research and industrial workflows. This article highlights its chemical attributes, applications in therapeutic development, and advantages over conventional building blocks.

Chemical Structure and Key Features

Boc-L-His(Trt)-Aib-OH (CAS 2061897-68-3) integrates three critical components:

1. Boc Protecting Group: Removed under acidic conditions (e.g., trifluoroacetic acid), Boc safeguards the α-amino group during peptide elongation while allowing orthogonal deprotection strategies.

2. Trt-Protected Histidine: The trityl group prevents undesired side reactions of histidine’s imidazole ring during synthesis, ensuring high purity and yield.

3. α-Aminoisobutyric Acid (Aib): This non-proteinogenic amino acid imposes conformational constraints, stabilizing α-helical or β-sheet structures in peptides.

The CAS registry 2061897-68-3 distinguishes this compound from similar derivatives, streamlining procurement and regulatory compliance.

Applications in Peptide-d Therapeutics

Boc-L-His(Trt)-Aib-OH (CAS 2061897-68-3) is pivotal in designing peptides with enhanced stability and bioactivity. Major applications include:

1. Antimicrobial Peptide (AMP) Development

Aib’s rigidity reduces peptide flexibility, minimizing enzymatic degradation and improving membrane permeability. Boc-L-His(Trt)-Aib-OH enables the synthesis of AMPs effective against multidrug-resistant bacteria.

2. Targeted Cancer Therapeutics

Histidine’s imidazole group facilitates pH-dependent drug release in tumor microenvironments. Peptides incorporating CAS 2061897-68-3 enhance the precision of chemotherapeutic delivery while reducing systemic toxicity.

3. Neuroactive Peptide Design

Aib-stabilized neuropeptides (e.g., analogs of ghrelin or neurotensin) exhibit prolonged half-lives in vivo, making them promising candidates for treating neurological disorders.

4. Vaccine Adjuvants and Immunomodulators

The Trt-protected histidine ensures clean synthesis of peptides used in vaccine formulations, where precise antigen presentation is critical for immune activation.

Advantages Over Standard Amino Acids

• Orthogonal Protection: Boc and Trt groups enable selective deprotection, ideal for synthesizing peptides with acid-sensitive residues.

• Enhanced Stability: Aib minimizes aggregation and proteolysis, extending peptide shelf life and in vivo efficacy.

• Scalability: Compatible with both solid-phase (SPPS) and solution-phase peptide synthesis, supporting industrial-scale production.

Safety and Regulatory Insights

• Handling: Use PPE (gloves, goggles) to avoid skin/eye contact.

• Disposal: Follow local regulations for organic waste containing Boc or Trt groups.

• Regulatory Status: Listed under CAS 2061897-68-3, this compound is non-hazardous but requires standard laboratory safety protocols.

Global Supplier: Pukang Biotechnology

Pukang Biotechnology delivers high-purity Boc-L-His(Trt)-Aib-OH (CAS 2061897-68-3) alongside custom peptide synthesis services. Their offerings include:

• GMP-Grade Production: For clinical and commercial applications.

• Technical Support: Optimization of Boc/Trt-d synthesis workflows.

• Rapid Global Shipping: Ensuring uninterrupted research progress.

Contact: +86-137-0808-4407 | export@pu-kang.com

Conclusion

Boc-L-His(Trt)-Aib-OH (CAS 2061897-68-3) is a cornerstone of modern peptide engineering, enabling the creation of stable, bioactive therapeutics for infectious diseases, oncology, and neurology. Its unique protection strategy and conformational control make it indispensable for researchers aiming to push the boundaries of peptide-d medicine.